Diagnostic yield of an ambulatory patch monitor in Emergency Department syncope patients unexplained after Emergency Department evaluation – a pilot study (PATCH-ED)
EMERGE are excited to announce the PATCH-ED study – aiming to recruit 100 patients, PATCH-ED will involve an ambulatory patch monitor being applied to monitor heart beats for 14 days in eligible patients who present with an episode of syncope that remains unexplained after full ED assessment. A patch report will be provided by iRhythm Technologies, Inc. San Francisco, CA enabling any arrhythmias to be identified and informing appropriate follow-up.
Study Aims: PATCH-ED aims to investigate the diagnostic yield, prevalence of events captured on patch monitor, patient satisfaction of patch monitor, patch compliance and influence on subsequent treatment in ED syncope patients.
Primary: Diagnostic yield of the ambulatory patch monitor for significant symptomatic arrhythmia at 90-day follow-up versus standard care strategies.
Sponsor: This study is sponsored by NHS Lothian.
Funding: Chest, Heart and Stroke Scotland
Setting: This is a single centre study being carried out in a teaching hospital ED, RIE.
Study Population: Patients presenting with an episode of syncope who after full ED assessment have no cause of syncope identified.
Syncope will be defined as a transient loss of consciousness (TLOC) with inability to maintain postural tone and immediate complete spontaneous recovery without medical intervention (to preexisting mental status and neurologic function)
Obvious underlying causes will be defined as:
Dr Matthew Reed
Kirsty Simpson, Research Nurse
Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine
10 Apr 2017 | Megan McGrath
EMERGE will soon begin recruitment to the new SNAP40 trial which will compare the new SNAP40 device with standard monitoring devices in the Emergency Department.Read more
23 Jan 2017 | Allan MacRaild
Heartbeats provide the rhythm of life. Interruptions to this rhythm are more likely to lead to a loss of consciousness than just a loss of spark. Rob Hannigan (pictured with Senior Research Nurse Allan MacRaild) took part in the PATCH-ED trial in 2016 following a number of unexplained blackouts. The results of his PATCH highlighted some dangerous arrhythmias including 24 seconds when his heart stopped beating entirely. Six months after his participation in the PATCH-ED trial, Rob met up with Allan to share his experiences.Read more
The purpose of this study is to test a new vaccine, ChAdOx1 nCoV-19, against COVID-19 in healthy volunteers.
The ChAdOx1 nCoV-19 vaccine has been developed in Oxford in an effort to protect healthy people from the pandemic. This study will evaluate the safety of the vaccine and its ability to generate an immune response against the virus.
This is a randomised trial. Participants will be randomly allocated to receive either the ChAdOx1 nCoV-19 vaccine, or a Men ACWY (meningitus vaccine). Volunteers will not be told which vaccine they will receive.
Participants will be asked to return for 6 visits across 12 months to evaluate their health.
Across the UK the trial aims to recruit 10,260 volunteers.
If you are interested in taking part, please click on this link and complete the online questionnaire: https://www.covid19vaccinetrial.co.uk/participate-edinburgh
The purpose of this study is to test a new vaccine against COVID-19 in healthy volunteers.
ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK)